

DongKwon Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9748326/publications.pdf>

Version: 2024-02-01

9
papers

40
citations

1937685

4
h-index

2053705

5
g-index

9
all docs

9
docs citations

9
times ranked

27
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical decision support algorithm based on machine learning to assess the clinical response to anti- programmed death-1 therapy in patients with non- small-cell lung cancer. European Journal of Cancer, 2021, 153, 179-189.	2.8	16
2	Primary Tumor Suppression and Systemic Immune Activation of Macrophages through the Sting Pathway in Metastatic Skin Tumor. Yonsei Medical Journal, 2022, 63, 42.	2.2	7
3	Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity. Frontiers in Oncology, 2022, 12, 821391.	2.8	6
4	SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models. Clinical and Translational Immunology, 2022, 11, e1364.	3.8	6
5	Abstract 1826: Comprehensive preclinical study on GI-101, a novel CD80-IgG4-IL2 variant protein, as a therapeutic antibody candidate with bispecific immuno-oncology target. Cancer Research, 2021, 81, 1826-1826.	0.9	5
6	Abstract 1787: YH29407, a novel IDO1 inhibitor, enhances the anti-tumor effects through increased tumor-reactive T cell functions in solid tumor. , 2021, , .		0
7	Abstract 1471: Incorporation of SKI-G-801, novel AXL inhibitor, with anti-PD-1 inhibitor plus chemotherapy improved anti-tumor activity and survival outcome via enhancing anti-tumor T cell immunity. , 2021, , .		0
8	572- Fibroblast activating protein (FAP)-targeting IL-12 (anti-FAP/IL-12) TME, potentiates anti-cancer effects in preclinical cancer models. , 2020, , .		0
9	Abstract 5481: Combination therapy with anti-PD-1 and YH29407, a novel IDO1 inhibitor, enhances T cell-mediated antitumor immunity in MC38 tumor-bearing mice. Cancer Research, 2022, 82, 5481-5481.	0.9	0